Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer
作者： Hyun Jeong Shim , Ju Young Yun , Jun Eul Hwang , Woo Kyun Bae , Sang Hee Cho
DOI: 10.1007/S10120-011-0032-6
关键词:
摘要: Background Almost all patients with advanced gastric cancer will eventually develop progressive disease after first-line chemotherapy. However, the role of subsequent salvage chemotherapy remains controversial. The purpose this study was to evaluate prognostic factors for survival who received third-line
springer.com
paperity.org参考文章(31)
Classification of adenocarcinoma of the oesophagogastric junction British Journal of Surgery. ,vol. 85, pp. 1457- 1459 ,(2003) , 10.1046/J.1365-2168.1998.00940.X
B. Glimelius, K. Hoffman, U. Haglund, O. Nyrén, P.O. Sjödén, Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Annals of Oncology. ,vol. 5, pp. 189- 190 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058778
Guillaume Piessen, Mathieu Messager, Emmanuelle Leteurtre, Triboulet Jean-Pierre, Christophe Mariette, Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Annals of Surgery. ,vol. 250, pp. 878- 887 ,(2009) , 10.1097/SLA.0B013E3181B21C7B
Andre M. Murad, Flavia F. Santiago, Andy Petroianu, Paulo R. S. Rocha, Marco A. G. Rodrigues, Marcelo Rausch, Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer. ,vol. 72, pp. 37- 41 ,(1993) , 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
Sang Hoon Ji, Do Hyoung Lim, Seong Yoon Yi, Hyo Song Kim, Hyun Jung Jun, Kyoung Ha Kim, Myung Hee Chang, Min Jae Park, Ji Eun Uhm, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer. ,vol. 9, pp. 110- 110 ,(2009) , 10.1186/1471-2407-9-110
Michael Stahl, Christian Müller, Wolf Köster, Hansjochen Wilke, Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy Onkologie. ,vol. 28, pp. 499- 502 ,(2005) , 10.1159/000087136
S Pyrhönen, T Kuitunen, P Nyandoto, M Kouri, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. ,vol. 71, pp. 587- 591 ,(1995) , 10.1038/BJC.1995.114
Yong Wha Moon, Sun Young Rha, Hei-Cheul Jeung, Chan Kim, Min Hee Hong, Hyun Chang, Jae Kyung Roh, Sung Hoon Noh, Byung Soo Kim, Hyun Cheol Chung, Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemotherapy and Pharmacology. ,vol. 66, pp. 797- 805 ,(2010) , 10.1007/S00280-010-1295-Z
John S. Macdonald, Gastric cancer--new therapeutic options. The New England Journal of Medicine. ,vol. 355, pp. 76- 77 ,(2006) , 10.1056/NEJME068121
V Catalano, F Graziano, D Santini, S D'Emidio, A M Baldelli, D Rossi, B Vincenzi, P Giordani, P Alessandroni, E Testa, G Tonini, G Catalano, Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? British Journal of Cancer. ,vol. 99, pp. 1402- 1407 ,(2008) , 10.1038/SJ.BJC.6604732